Compares two robotic surgery systems for prostate and kidney cancer operations
Compares the HUGO RAS and da Vinci robots in adults with prostate or kidney cancer.
Plain-language title generated from the registry record
Registry title: Comparison Between HUGO RAS Robotic Platform and Da Vinci Robotic Platform
Key facts
- Where
- Bologna, ItalySee the site
Where in Italy
- IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Trial code
- NCT06844513
- Record updated
- 25 February 2025
- Original description
The study is designed as a single-center, prospective, interventional, non-pharmacological, randomized, open-label, controlled trial with parallel groups. It targets patients with prostate cancer or kidney cancer who are candidates for robot-assisted surgical treatment, specifically radical prostatectomy (RP) or partial nephrectomy (PN).Read full original descriptionShow less
HUGO RAS Robotic Platform for Radical Prostatectomy and Partial Nephrectomy: Comparison with the Da Vinci Robotic Platform
The study is designed as a single-center, prospective, interventional, non-pharmacological, randomized, open-label, controlled trial with parallel groups. It targets patients with prostate cancer or kidney cancer who are candidates for robot-assisted surgical treatment, specifically radical prostatectomy (RP) or partial nephrectomy (PN).
Inclusion: Patients with Prostate Cancer (Group A); Age ≥ 18 years; Life expectancy greater than 10 years; Diagnosis of prostate cancer following prostate needle biopsy; Clinical stage cT1-T3b, N0-1 disease; Positive anesthetic fitness assessment for robot-assisted radical prostatectomy; Provision of informed consent for the study; Patients with Kidney Cancer (Group B); Age ≥ 18 years; Radiological diagnosis of organ-confined kidney cancer at clinical stage T1a or T1b; Underwent CT and/or MRI of the abdomen with contrast medium; Positive anesthetic fitness assessment for robot-assisted partial nephrectomy; Provision of informed consent for the study.
Exclusion: Expression of a preference for radical treatment other than surgery (e.g., external radiotherapy); Patients with Prostate Cancer (Group A); Metastatic prostate cancer (M1); Other conditions deemed by healthcare professionals to contraindicate inclusion in the study; Patients with Kidney Cancer (Group B); Metastatic kidney cancer (M1); Other conditions deemed by healthcare professionals to contraindicate inclusion in the study; Indication for radical nephrectomy.